Belcher Pharmaceuticals Called Out for Raising Price of Old Drug

Belcher Pharmaceuticals Called Out for Raising Price of Old Drug

Old drugs are often repurposed, or re-entered
into the pharmaceutical market, for their potential to treat medical afflictions
in a new way. With Belcher Pharmaceuticals and their recent actions concerning
Ablysinol, a dehydrated alcohol solution used in certain heart procedures, this
is not the case.

In a statement on
LinkedIn, Codiak
BioSciences CEO Douglas Williams and seven other biotech CEOs singled
out Seminole, Florida-based Belcher Pharmaceuticals, based on the Food and Drug
Administration approval earlier this month of Ablysinol (dehydrated alcohol),
an old drug used in certain heart procedures. The company received the approval
not by conducting clinical trials on its own, but through a pathway known as
505(b)(2), whereby it was based on a review of data from 38 publications by
other parties.

A Price Increase of Nearly $9,000

Belcher’s executives claimed to have invested multiple millions of dollars into
Ablysinol’s approval, the pathway they took was relatively cheaper than it
would have been if they had discovered and developed the drug on their own.
Nevertheless, as reported by
STAT, the company received seven years of mar...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee